When T2D subjects were stratified according to ACE inhibitor (ACEi) therapies, there was no difference in sNRP1 levels in subgroups at either glucose normalization or hypoglycaemia (Figure 2C). This evidence concerns the gene ACE and type 2 diabetes mellitus.